12:00 AM
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pegasys peginterferon alfa-2a regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending the use of Pegasys peginterferon alfa-2a from Roche and ViraferonPeg peginterferon alfa-2b from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) both in combination with ribavirin to treat chronic...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >